Sana Biotechnology, Inc. filings document the regulatory record for a public biotechnology company developing engineered-cell medicines. Recent 8-K reports disclose operating results, corporate presentations, program updates for UP421, SC451, and SG293, at-the-market common stock sales arrangements, executive appointments, and board-class governance matters.
Proxy materials describe annual meeting voting items, director elections, board structure, executive compensation, and stockholder governance procedures. The company’s filings also capture material agreements, capital-structure disclosures, Regulation FD presentations, and other event reports tied to its cell-therapy pipeline and public-company obligations.
Sana Biotechnology, Inc. director Hans Edgar Bishop acquired 8,680 shares of common stock on October 5, 2026. The award consisted of fully vested restricted stock units. His reported direct common-stock holdings following the transaction were 5,863,480 shares.
Sana Biotechnology, Inc. (SANA) furnished an updated corporate presentation describing its pipeline and strategy for cell and gene-based therapies, including programs in type 1 diabetes and in vivo CAR T cells. The information is provided under a Regulation FD-related disclosure and is not deemed filed under the Exchange Act.
The presentation highlights SC451, a hypoimmune stem cell-derived islet cell therapy for type 1 diabetes, with a 2026 goal to file an IND and start a Phase 1/2 trial, and in vivo CAR T programs SG293 and SG227, with potential early clinical data and trial starts around 2027. It also summarizes first-in-human data with hypoimmune islet cells (UP421) showing immune evasion and sustained function without immunosuppression.
Sana Biotechnology, Inc. (SANA) reported insider equity transactions by EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel. On August 26, 2026, he exercised 125,000 Restricted Stock Units, receiving 125,000 shares of common stock, and his RSU position was reported as 250,000 units afterward. On August 27, 2026, 41,158 common shares were delivered or withheld at $4.11 per share for payment of exercise price or tax liability related to the equity award.
Sana Biotechnology, Inc. received an updated ownership report from a group of ARCH venture funds and related entities, plus several individual managers, regarding their holdings of Sana common stock.
As of June 30, 2026, the ARCH-related reporting persons collectively report beneficial ownership or shared power over 45,860,681 shares of Sana common stock, representing 15.3% of the class, based on 299,360,637 shares outstanding as of August 3, 2026. One manager, Robert Nelsen, also holds vested options for 298,591 shares, 1,353 fully vested RSUs, and a related family trust holds 12,500 shares, bringing his reported beneficial ownership to 46,173,125 shares, or 15.4% of the class, assuming exercise of his vested options. The filing details how voting and dispositive power over these shares is shared among multiple ARCH funds, general partners and investment committee members, and includes standard disclaimers that each reporting person only admits beneficial ownership of shares held of record in its or his own name.
Sana Biotechnology, Inc. is a development-stage cell therapy company with no approved products, focused on engineered cell medicines for type 1 diabetes and in vivo CAR-T therapies (SC451, SG293, SG227). For the six months ended June 30, 2026, it reported a net loss of $110.8 million, improved from $143.2 million in 2025, and an accumulated deficit of $2.0 billion.
Cash, cash equivalents, and marketable securities totaled $160.5 million, while net cash used in operating activities was $70.2 million, indicating high cash burn. Management states that current capital resources may not fund operations for 12 months and that there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity in 2026, Sana raised approximately $68.6 million via an at-the-market equity facility and about $25 million from a stock purchase agreement with Mayo Clinic, which also includes a collaboration and license arrangement. Additional capital may come from Mayo’s option to buy further shares and from up to $150.0 million of future ATM sales. The balance sheet also includes sizable fair-value liabilities for Cobalt acquisition contingent consideration of $150.8 million and success payment liabilities of $24.5 million.
Sana Biotechnology, Inc. reported second quarter 2026 results and updates on its cell and gene therapy pipeline. The company is preparing to start a Phase 1/2 trial for SC451, a hypoimmune iPSC-derived pancreatic islet cell therapy for type 1 diabetes, and to begin clinical studies and generate first-in-human data for SG293 in non-Hodgkin lymphoma as early as 2026. Sana also advanced SG227, a BCMA-directed CAR T fusosome for multiple myeloma, with clinical testing targeted as early as mid-2027.
The company highlighted 14‑month data from an investigator-sponsored study of UP421, showing survival and function of transplanted hypoimmune islet cells without immunosuppression and no identified safety issues. A strategic collaboration with Mayo Clinic, which includes a $25.0 million equity investment, is intended to accelerate SC451 development. Cash, cash equivalents, and marketable securities were $160.5 million as of June 30, 2026, supported by $93.3 million in net equity proceeds in the quarter, and Sana projects a cash runway into mid‑2027. Second quarter GAAP net loss was $63.6 million (vs. $93.8 million a year earlier), and non‑GAAP net loss was $39.7 million, with non‑GAAP operating cash burn of $69.3 million for the first half of 2026.
Sana Biotechnology director Hans Edgar Bishop reported an equity award. He received 6,297 shares of Common Stock as a grant with a price per share of $0.00, consisting of fully vested restricted stock units. After this compensation-related acquisition, his directly held stake increased to 5,854,800 shares.
Sana Biotechnology director Patrick Y. Yang received a new stock option grant, giving him the right to acquire 90,000 shares of common stock at an exercise price of $2.96 per share. The option vests in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, as long as he continues providing service to the company. Following this award, he holds 90,000 derivative securities linked to Sana common stock directly.
Sana Biotechnology director Robert L. Rosiello received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, assuming he remains in continuous service.
Sana Biotechnology director Michelle Seitz received a grant of stock options for 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest and become fully exercisable on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual stockholder meeting, as long as she continues to provide service to the company through that date. Following this award, she holds 90,000 stock options directly, reflecting a compensation-related acquisition rather than an open-market share purchase.